April 29, 2024: We strongly support today’s FDA’s decision to regulate lab-developed tests. Unfortunately, FDA’s final rules has compromised on the critical issue of grandfathering thousands of tests on the already on the market.
Read More »On Health Policy
NCHR Comments on CMS’ Proposed Rule On Strengthening the Oversight of Accrediting Organizations and Preventing Conflict of Interests, and Related Provisions
April 16th, 2024: NCHR supports CMS’ proposed rule and policies to increase oversight of Medicare accrediting organizations by addressing conflicts of interest; establishing standards, processes, and definitions for state surveys and unannounced surveys; and revising the validation survey program. We provide four key recommendations to bolster CMS’ proposal.
Read More »Letter to Sen. Sanders in Support of the Childhood Diabetes Reduction Act
April 12, 2024: This bill takes important steps to adequately inform consumers about the known risks of foods marketed to children and often consumed by all family members
Read More »NCHR Comment on Labeling and Advertising of Beverages with Alcohol Content
April 4, 2024: NCHR advocates for mandatory labeling of alcohol beverages that includes portion size information about alcohol content, calories, allergens, and other ingredients. We explain why voluntary standards are inadequate and that consumers need and deserve the information that would enable them to make safe and healthy decisions.
Read More »NCHR Provides Testimony at the Presidential Advisory Council Meeting on Combating Antimicrobial Resistance
March 15, 2024: NCHR provided testimony at the Presidential Advisory Council Meeting on Combating Antimicrobial Resistance. We advised that AMR research should move away from using pathogen-specific metrics and focus on patient-centered metrics. This will help to improve our current understanding of the clinical significance of resistant and nonresistant bacterial infections.
Read More »